Paralos Bioscience

Overview

Custom M13 phage display production from customer sequences: individual constructs with full-vector sequence verification, and defined pooled libraries with quote-specific QC, for research use. Additional work requires scope review and written confirmation.

Funding and backers

Total raised
$647k
1 round on record
Latest round
$647k
Venture round · Jul 2025 · 15 mo ago
Revenue
$1M
2025 · SEC Form D 0002080259-26-000002
The money's age
Due for its next round
15 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 28, 2025 Raised a round Venture round $647k · SEC Form D 2024 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Jul 2025 $647k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Paralos Bioscience Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Irene ChenExecutive Officer, DirectorSEC Form D
Yanxi YangExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Antler
backs Orbion
Techstars
backs Musa
8VC
backs seqholdings
The Creator Fund
backs BioPhoundry
Nordic Science Investments
backs PrecisionPhage
Similar startupsby what they do, their industry and backers
PrecisionPhageFounded 2025 · 201-500 employees
PrecisionPhage empowers you with cutting-edge phage bioinformatics software. We have phage laboratory services and an extensive phage…
OrbionFounded 2025
Orbion is an AI protein-intelligence platform. From a sequence, it characterizes structure and function, ranks stabilizing mutations…
BioPhoundryVenture round $1.1M · 22 mo ago · Founded 2024 · 1-10 employees
T h e E n g i n e o f P h a g e I n n o v a t i o n. Revolutionizing healthcare with faster, affordable, and scalable phage solutions.
seqholdings4 roles
Sequence Holdings is a technology holding company that acquires established businesses and transforms them with artificial intelligence.
Musa
Capital is not scarce. It is misrouted. Musa is the system that structures, sequences, and routes capital to SMEs globally.
EpiVaxVenture round $425k · 6 yr ago · Founded 2017 · 51-200 employees
EpiVax leads the industry in immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines. Utilizing…

Visa sponsorship

#5,755 of 8,998 sponsors
United StatesUS 1
1
H-1B filings in 12 months
$133k
Median offered salary
0
Open roles in United States
Who they sponsor
Biochemists and biophysicists
1
The salary offered for each occupationVisa pass · 90 credits
In the register as Paralos Bioscience Inc., Los Angeles, CA
Alert me
US Department of Labor · latest filing May 8, 2026 · Visa details by country

Financials

Est. Annual Revenue
$500k
2025
Total raised
$647k
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $647k Details

People

Irene Chen
Executive Officer, Director
SEC Form D
Yanxi Yang
Executive Officer
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Los Angeles United States
HQ
Paralos Bioscience Inc.
570 Westwood Plaza, Suite 6350, Los Angeles, CA 90095
company site